|
|
Posts Tagged ‘Enbrel’
January 25th 2012 | Biologics, Patient Stories, Psoriasis Cure Now, Psoriasis Research, psoriatic arthritis, Public policy issues | 4 Comments
Before 2011 becomes a distant memory, Psoriasis Cure Now felt it would be useful to highlight what we believe were the top psoriasis and psoriatic arthritis stories of 2011. The year included bad news about a promising treatment from Abbot buy cialis online uk t, as well as a psoriasis sub-plot to one of the
READ THE FULL POST
March 2nd 2011 | Biologics, Health care system, psoriatic arthritis, Public policy issues | 1 Comment
We’re happy to see the Phil Mickelson psoriasis, psoriatic arthritis, and RA campaign launch. Go Phil! We hope he is winning again soon. The campaign is called On Course with Phil, and you can see the site here:
November 8th 2010 | Patient Stories, psoriatic arthritis | 4 Comments
In the not-very-surprising news department, Amgen & Pfizer, the companies that market Enbrel (etanercept), have signed up
October 11th 2010 | Biologics, Psoriasis Research, Side-effects of treatment, Treatment | 11 Comments
[UPDATE 1/14/2011: Abbott today announced that it has withdrawn its application with the U.S. FDA to market briakinumab (ABT-874, Ozespa). Our full analysis of Abbott's pulling its briakinumab application is here. Our original, unedited post concerning the Phase Three trials is below.] You know that buzz about Centocor Ortho Biotech’s biologic Stelara (ustekinumab), the first
READ THE FULL POST
July 16th 2010 | Biologics, Psoriasis Research, Treatment | 1 Comment
Briakinumab, an experimental psoriasis treatment from Abbott (the folks who bring us Humira [adalimumab]), continues to rack up favorable results in clinical trials. Most recently, it beat the market-leading biologic treatment Enbrel [etanercept] an rocket italian d of course a placebo (i.e., a fake treatment) in a 12-week test. This follows its amazing Phase Two
READ THE FULL POST
September 20th 2008 | Biologics, Treatment | 0 Comments
An experimental psoriasis treatment that could be approved for use in psoriasis patients by the end of 2008 edged out the leading psoriasis biologic in a 12-week head-to-head clinical trial. Ustekinumab (likely brand name, Stelara), made by Johnson & Johnson’s Centocor unit, helped more patients achieve 75% and 90% improvements in skin symptoms than did
READ THE FULL POST
March 18th 2008 | Biologics, Treatment | 0 Comments
Enbrel’s prescribing information will now have a black box warning to highlight the small but potentially serious risk of infections, including tuberculosis. In U.S. and Canadian clinical trials, the rate of tuberculosis infection has been roughly 0.007% of patients, or about 1 in 14,000 cases; but in actual practice, rare cases of tuberculosis have been
READ THE FULL POST
|
|
|
